Bioelectronica

A research-stage biotechnology company building next-generation digital tools for drug discovery, diagnostics, and cell sorting. The company is one of the leading entities using the advances behind Moore’s law and passing those benefits on to biochemists. Bioelectronica invented “electrofluidic chips,” which are built through planar processes to solve a core problem in biochemistry and cell biology: manipulating small (nanoliter) volume of liquids and detecting chemical or biochemical reactions inside them. This is an inexorable advancement for drug developers and other cell biologists as electrofluidic chips are scalable to billions of nanopore channels, which can be used to transport and sort single cells based on their secretion rate and other properties

bioelectronica.com

BloqcubeTM

With a focus on accelerating clinical trials and cost benefits to trial owners, BloqCube, a pharma technology provider, is changing the current state of digital implementations by taking the tests to the patient rather than them being treated at trial sites. As strict regulations come into play in terms of data management, BloqCube uses blockchain to safeguard all information in a secure and decentralized manner, reassuring stakeholders that their information is always safe and well protected. For pharma institutions and drug development centers working on areas that need the most medical attention, BloqCube addresses critical pain points that are plaguing their operational workflows

bloqcube.com

IHMA

Provides a full suite of technical capabilities and domain expertise in all phases of anti-infective drug development

ihma.com

Intelligencia.ai

Backed by a robust interdisciplinary team of software engineers, AI practitioners, scientists, and drug developers, Intelligencia leverages a proprietary methodology to deliver its solution to the researchers. This platform pulls information from hundreds of characteristics that are fed into various algorithms to pick up trends in order to answer the questions of drug developers. Whether it be to assist in prioritization of pre-clinical assets to take forward to the clinic, help to make critical go/no-go decisions on development or to evaluate potential compounds to in-license, Intelligencia provides an objective outside view deemed valuable by pharma and biotech today

intelligencia.ai

NTxBio

NTxBio’s science is redefining the discovery and production of biologic materials to be infinitely faster, purer, and more affordable for everyone. They are moving beyond empowering biopharma to impact global health and humanity. Large scale production of pharmaceuticals follows the convention of growing material in an environment typically hosted by E. coli bacteria. From insulin to vaccines to modern drugs, this complicated, time-consuming, and inefficient process is the reason behind the extreme costs and long delays. Not to mention the vast and sometimes toxic waste stream produced with each batch, NTx’s science is changing it all

ntxbio.com

Rosa & Co.

Rosa was first found in 2002 and remained an employee-owned, science-focused, and client-friendly firm. In present times, Rosa is the worldwide commercial leader in PhysioPD-style Research, with comprehensive basic biology and therapeutic experience, industry-leading modeling expertise, and repeat research engagements with a majority of the Top 20 pharmaceutical companies. Rosa’s staff brings more than a century of aggregate experience in applying PhysioPD Research to the inherent challenges faced by drug developers and has authored hundreds of scientific posters, conference presentations, relevant patents, and peer-reviewed publications

rosaandco.com

BioXcel Therapeutics

BioXcel Therapeutics is a clinical-stage biopharmaceutical company that uses novel AI, to identify the next wave of medicines across neuroscience and immuno-oncology. They are focused on leveraging cutting-edge technology and innovative research to develop high-value therapeutics aimed at transforming patients’ lives. BioXcel Therapeutics employs a unique AI platform to minimize therapeutic development costs and potentially accelerate timelines while aiming to increase the possibility of success. Their approach leverages existing approved drugs and clinically evaluated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices

BlueCatBio

The award-winning BlueWasher of BlueCatBio uses centrifugation instead of aspiration to remove liquids from all plate formats, including 1536w, eliminating background and variability at their (assay) sources. Engineered and built in Germany to the highest quality standards, BlueWasher offers unprecedented control and reproducibility of non-contact plate drying, media changes, and bead washes through an intuitive and user-friendly graphical user interface and is built to be easily automated. BlueWasher instantly improves screening economics without complex assay or automation changes, delivering unparalleled ROI and a direct boost to overall drug discovery productivity

Tempo Bioscience

Established in 2013, Tempo Bioscience, Inc (Tempo) develops human adult stem cell-based cell models and biosensor enabling technologies for preclinical drug discovery & development, biobanking, in-vitro diagnostics, and biomarker development. Their in-house developed proprietary technologies and cell-based products serve as valuable tools for the Biotechnology and Pharmaceutical industry. Tempo Bioscience (Tempo) develops cutting-edge 2D&3D human cellular technologies to serve the needs of a variety of preclinical research and drug development pipelines across unique and diverse therapeutic and diagnostic areas. Tempo offers services and alliances based on advanced technological platforms and a range of capabilities

XtalPi

XtalPi is a pharmaceutical technology organization that is recreating the industry’s approach to drug research and development with the help of its Intelligent Digital Drug Discovery and Development (ID4) platform. With interwoven quantum physics, AI, and high-performance cloud computing algorithms, XtalPi’s ID4 platform offers accurate predictions on the physicochemical and pharmaceutical properties of small-molecule candidates for solid-form selection, drug design, and other critical aspects of drug development. XtalPi is committed to improving the efficiency, precision, and success rate of drug research and development, and contributing to a healthier society worldwide